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Abstract: Migrants, defined as individuals who move from their country of origin to another,
account for 40% of newly-diagnosed cases of human immunodeficiency virus (HIV) in the European
Union/European Economic Area (EU/EEA). Populations at high risk for HIV include migrants,
from countries or living in neighbourhoods where HIV is prevalent, and those participating in high
risk behaviour. These migrants are at risk of low CD4 counts at diagnosis, increased morbidity,
mortality, and onward transmission. The aim of this systematic review is to evaluate the effectiveness
and cost-effectiveness of HIV testing strategies in migrant populations and to estimate their effect on
testing uptake, mortality, and resource requirements. Following a systematic overview, we included
four systematic reviews on the effectiveness of strategies in non-migrant populations and inferred
their effect on migrant populations, as well as eight individual studies on cost-effectiveness/resource
requirements. We assessed the certainty of our results using the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) approach. The systematic reviews reported that
HIV tests are highly accurate (rapid test >90% sensitivity, Western blot and ELISA >99% sensitivity).
A meta-analysis showed that rapid testing approaches improve the access and uptake of testing
(risk ratio = 2.95, 95% CI: 1.69 to 5.16), and were associated with a lower incidence of HIV in the
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middle-aged women subgroup among marginalised populations at a high risk of HIV exposure
and HIV related stigma. Economic evidence on rapid counselling and testing identified strategic
advantages with rapid tests. In conclusion, community-based rapid testing programmes may
have the potential to improve uptake of HIV testing among migrant populations across a range of
EU/EEA settings.
Keywords: HIV; AIDS; stigma; refugees; migrants
1. Introduction
Migrants, encompassing a broad range of subgroups (i.e., asylum seekers, refugees, undocumented
and economic migrants, foreign students, etc.), are individuals who move from their country of
residence to another. Populations at unique high risk for human immunodeficiency virus (HIV) include
migrants from countries where HIV is prevalent, living in neighborhoods where HIV is prevalent,
and participating in high-risk behaviour [1]. In 2016, 29,444 new HIV infections were diagnosed in
the European Union/European Economic Area (EU/EEA) [2]. Although the overall number of HIV
diagnoses in migrants from high-prevalence countries have declined in the EU/EEA over the past
decade, migrants still accounted for 40% of the reported cases in 2016 (range 1–80%) [2]. HIV acquisition
among migrants was thought to occur pre-migration, but recent EU/EEA evidence [3–6] suggests
post-migration acquisition is also of concern and this suggests community based targeted interventions,
including screening programmes, which may be needed many years after arrival to the EU/EEA.
About 15% of all people living with HIV (n = 122,000) in the EU/EEA are unaware of their HIV positive
status [7], making accurate data on HIV prevalence among migrant populations in the EU/EEA
difficult. Those with an increased risk of HIV infection include migrants from HIV endemic regions,
men who have sex with men (MSM), those with multiple sex partners, and injection drug users
(IDU) [8].
In an effort to scale up diagnosis and treatment programmes, the Joint United Nations Programme
on HIV/acquired immunodeficiency syndrome (AIDS) (UNAIDS) outlined the 90–90–90 treatment
target to help end the AIDS epidemic. By 2020, 90% of those with HIV will know their status, 90% of all
people with HIV will receive sustained antiretroviral therapy (ART), and 90% of all people receiving
ART will have viral suppression [9]. In response to the variability in the testing and treatment
approaches for HIV across EU/EEA countries, the European Centre for Disease Prevention and
Control (ECDC) published guidelines on HIV testing [10]. Most countries have reported having
guidance for HIV testing at the ational level [11,12]. At least 22 countries acknowledge that migrants
are vulnerable to HIV infection, but six of these do not explicitly recommend HIV testing options
for migrant populations [13]. Additionally, these testing options are often inconsistent between and
within countries. Currently, there are no EU/EEA-wide HIV testing recommendations or strategies
specifically tailored for migrant populations.
Conventional HIV testing is defined as traditional laboratory testing in healthcare settings,
where patients have to wait days to weeks to receive their results; this testing approach includes
an ELISA test followed by a Western blot. Rapid HIV testing refers to voluntary enrolment where results
are obtained within hours, followed by a confirmatory test, and with links to outreach counselling
for results and treatment options [14]. Rapid testing strategies are feasible for field settings, and the
WHO recommends rapid testing as part of the community based testing strategy for communities
with persistent HIV-related stigma [15].
In 2015, the World Health Organization (WHO) published consolidated guidelines on the use
of antiretroviral drugs for treating and preventing HIV infection [15]. This public health approach
advocated by the WHO considers the collective health status of a population, to ensure wide access
to high quality services using simplified and standard HIV testing approaches, such as conventional,
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community-based, and other rapid testing techniques [15]. Migrants from Sub-Saharan Africa and
Latin America are more likely to be diagnosed late (defined as having a CD4 count of less than
350 CD4+ cells/mm3) in comparison to non-migrant Europeans [2,8]. Late diagnosis increases the
disease transmission rate, and increases the risk of morbidity and mortality [16]. The main reasons
for late diagnosis among migrants are believed to include impaired access to testing as a result of
HIV-related stigma, fear, guilt, economic difficulties, and difficulties accessing health care in Europe [8].
This review focuses on the newly arrived migrants to the EU/EEA, who migrated within the past five
years, with consideration given to country and origin, circumstances of migration, gender, and age,
where relevant. This group of migrants is often less well integrated into health systems because
of a lack of reliable access to health services, poor information about healthcare, lack of supportive
language provision, and inattention to the gender dimensions of healthcare [17]. While marginalized
migrants were the specific focus, we recognize that other migrant populations may also benefit from
this review. We conducted a systematic review on the effectiveness, as well as a second systematic
review on the cost-effectiveness, of screening for HIV among migrants in the EU/EEA region, with the
aim of informing the development of ECDC migrant screening guidance.
2. Methods
Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE)
approach; the Campbell and Cochrane Collaboration Equity Methods Group; and a review team
including clinicians, public health experts, and researchers from across the EU/EEA, to conduct the
evidence syntheses. A detailed description of the methods can be found in the registered systematic
review protocol [18].
The review group followed the PRISMA reporting guidelines [19] for the reporting of this
systematic review (PROSPERO [CRD42016045798]). In summary, the review team developed key
research questions (PICO: population, intervention, comparison, and outcome) and a logic model
showing an evidence chain to identify key concepts, to consider potential role of indirect evidence
related to populations and interventions, and to support the formulation of search strategies
(see Appendices A and B) [18]. The review teams aimed to answer the following overarching questions.
• Should newly arrived migrants be screened for HIV? Who should be targeted and how?
• What implementation considerations should be considered when screening for HIV in newly
arrived migrants to the EU/EEA?
‘Migrants’, a focus for the eligible evidence, included asylum seekers, refugees, undocumented
migrants, and other foreign-born residents, with a focus on newly arrived migrants from HIV
intermediate (>0.1%) and high (>1%) prevalence countries to EU/EEA in the last five years.
Our analysis did not consider specific subgroups of migrants, but rather, it focused on those that
were at high risk of exposure and facing poor access to testing and treatment. This review included
various rapid testing approaches and provider-initiated testing approaches. Evidence was evaluated
using a hierarchical approach, whereby systematic reviews/meta-analyses, and evidence based
guidelines were given the most weight, followed by individual randomized controlled trials (RCTs),
quasi-experimental studies, and observational studies [20,21]. The availability of existing high quality
systematic reviews on these topics led us to follow a review of reviews methodology, thereby excluding
all of the articles that were not systematic reviews. The team sought to build on existing high quality
evidence and to identify gaps that may exist in the evidence-base.
Relevant search terms and strategies were used to search published literature in Ovid MEDLINE,
Database of Abstracts of Reviews of Effects (DARE), Cochrane Database of Systematic Reviews (CDSR),
and EMBASE from 2010 to December 2016, and NHS EED, CEA Registry (Tufts University), and Google
Scholar from 1995 to 2016 (See Appendix B), and grey literature through Google, as well as the U.S.
Centres for Disease Control and Prevention (CDC), ECDC, UNAIDS, and WHO websites. The general
search terms used included “HIV”, “AIDS”, “screening”, “early diagnosis”, and “disease surveillance”
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(see Appendix B for complete search strategy). No language restrictions were applied to the searches.
Migrants and refugees were key populations of interest, but we also considered studies that included
marginalised populations with a high prevalence of HIV.
Two independent team members (Tamara Lotfi and Lama Kilzar) manually reviewed the titles,
abstracts, and full text of identified citations; selected evidence for inclusion; and compiled evidence
reviews and PRISMA flow sheets. Disagreements were resolved by consensus or the involvement of a third
reviewer. We assessed the methodological quality of the potentially included studies with AMSTAR [22]
or Newcastle Ottawa Newcastle Scales [23]. For evidence of cost-effectiveness, we extracted data
from relevant study designs (e.g., micro-costing studies, within-trial cost-utility analyses, and Markov
models) for three specific questions, namely: the size of the resource requirements, the certainty
of evidence around resource requirements, and whether the cost-effectiveness results favoured the
intervention or comparator [24]. Finally, we assessed the certainty of the economic evidence in each
study using the relevant items from the 1997 Drummond checklist [25]. The team created tables
showing the characteristics of the included studies (see Tables 1 and 2), then rated the certainty of the
effects for pre-selected outcome measures, and finally, conducted meta-analyses and created GRADE
evidence profiles.
The final analysis report was on the GRADE synthesis. The certainty of the evidence rating reflects
the level of confidence in an estimate of the desirable and undesirable effects. The implementation
considerations were informed by exisiting literature.
3. Results
We retrieved 4241 articles on the effectiveness of HIV testing options. After the removal of
duplicates, 3158 studies were screened by title and abstract for eligibility, based on our PICO criteria
(see Table A1 in Appendix C). Of these, 34 studies were screened for full-text, and 30 studies were
excluded at the full-text stage. The reasons for exclusion were that the intervention was not HIV testing
(n = 25), conference abstract (n = 1), and not a systematic review (n = 4). Four systematic reviews
were included in the end [26–29] (see Figure 1a). Additionally, 7346 economic studies were identified.
After the removal of duplicates, we screened 6241 titles and abstracts for eligibility, and filtered the
remaining records with “cost” and “review” in the title or abstract. Of the remaining 13 articles,
12 articles were selected for a full-text review. Eight studies were included [30–37] (see Figure 1b).
Four studies were excluded, as a result of relevance to our PICO criteria.
Our systematic review evaluated voluntary HIV testing approaches among migrants from
HIV intermediate (>0.1%) and high (>1%) prevalence countries arriving to the EU/EEA.
This included various rapid testing approaches and provider-initiated testing approaches. Only one
randomised-controlled trial (RCT), from the United States [38], explicitly identified migrants within
their study population. This study was included in Pottie (2014). The GRADE methodology to assess
the certainty of evidence considers differences in the study populations and interventions (indirectness)
as a potential reason to downgrade the level of certainty (See Table 3), allowing us to interpret the
findings consistently for the migrant populations [39]. None of the systematic reviews contained
any RCTs or observational studies comparing clinical outcomes between indiviuals screened or not
screened for HIV infection. No RCT or observational study evaluated the value of repeat HIV testing
compared with one-time testing, or of different strategies for repeat testing. No studies compared the
effects of different pre- or post-test HIV counselling methods on testing uptake or rates of follow up,
and linkage to care.
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Table 1. Characteristics of included studies (effectiveness). HIV—human immunodeficiency virus; EU/EEA—European Union/European Economic Area;
RCT—randomised-controlled trial; RR—relative risk; WHO—World Health Organization; CI—confidence interval; SMS—short message service.
Study Design and Quality Included Studies Population Intervention Results/Outcomes
Should Voluntary Testing for HIV Infection be Offered to all Recently Arrived Migrants to the EU/EEA?
Pottie et al., 2014 [26] Systematic reviewAMSTAR 9/11
n = 13
1. Anaya et al. (RCT, n = 251, United States of America).
2. Coates et al. (cRCT, n = 115,900, Tanzania, Zimbabwe, Thailand,
and South Africa).
3. Lugada et al. (cRCT, n = 7184, Uganda).
4. Malonza et al. (RCT, n = 1249, Kenya).
5. Read et al. (RCT, n = 400, Australia).
6. Spielberg et al. (cRCT, n = 17,007, United States of America).
7. Sweat et al. (cRCT, n = 57,156, Tanzania, Zimbabwe, and Thailand).
8. Walensky et al. (RCT, n = 4855, United States of America).
9. Appiah et al. (cross sectional, n = Not reported Ghana).
10. Huebner et al. (Controlled before-after study n = NR,
United States of America).
11. Liang et al. (cohort, n = not reported United States of America).
12. Shrestha et al. (cohort, n = not reported United States of America).
13. White et al. (cohort, n = not reported, United States of America).
Individuals at high risk
of exposure
Facilitated voluntary
enrolment; use of
a rapid-testing approach
(providing results within
24 h); outreach counseling,
delivery of results and
treatment options.
Receipt of HIV test results: Increased
likelihood among participants randomized to
the rapid approach study arms to receive test
results (RR = 2.14, 95% CI 1.08 to 4.24)
(n = 3; RCTs).
Repeat HIV testing and test incidence rate:
increased HIV repeat testing among those in
the intervention arm (RR = 2.28,
95% CI 0.35 to 15.07) (n = 1; cluster RCT).
HIV incidence 36-month period in five
countries showed an 11% reduction in
estimated incidence in intervention RR = 0.89,
95% CI = 0.63 to 1.24).
Treatment program uptake: OR = 1.7, 95% CI
0.8 to 3.7 for the uptake of perinatal HIV-1
interventions between rapid VCT versus
conventional VCT (n = 1)
Kennedy et al.,
2013 [27]
Systematic Review
AMSTAR 5/11
n = 19
1. Allen et al. (time series, n = 1458, Rwanda).
2. Allen et al. (non-randomized trial, n = not reported, Rwanda).
3. Allen et al. (time series, n = 1438, Rwanda).
4. Bentley et al. (time series, n = 1628, India).
5. Brou et al. (time series, n = 980, Cote d’Ivoire).
6. Chamdisarewa et al. (cross sectional, n = 4872, Zimbabwe).
7. Creek et al. (cross sectional, n = 1456, Botswana).
8. Desgrees-Du-Lou et al. (cohort, n = 937, Cote d’Ivoire).
9. Harris et al. (cross sectional, n = not reported, Zambia).
10. Huerga et al. (cross sectional, n = 409, Kenya).
11. Khoshnood et al. (RCT, n = 600, China).
12. Kiene et al. (before–after, n = 245, Uganda).
13. Moses et al. (cross sectional, n = not reported, Malawi).
14. Pang et al. (cross sectional, n = 585, China).
15. Stringer et al. (cRCT, n = 246, Zambia).
16. Van Rie et al. (nRCT, n = 1238, DRC).
17. Van’t Hoog et al. (cross sectional, n = 4142, Kenya).
18. Wiktor et al. (time series, n = 559, Cote d’Ivoire).
19. Xu et al. (time series, n = 779, Thailand).
Low- and middle-income
countries; health care
setting where individuals
were seeking health care
services other than HIV
testing. Individuals,
couples, or groups had to
receive pre- and post-test
counseling about HIV and
an HIV test
Provider-initiated testing
and counseling (PITC)
(aligned with the
2007 WHO).
The majority of studies were conducted before
WHO PITC guidelines were developed,
indicating that provider-initiated testing was
occurring in many locations prior to
global guidance.
All studies included in this review that
reported rates of HIV testing uptake showed
increases associated with a PITC approach.
Comparing behavior in the three months
preceding PITC to behavior in the three
months after PITC, the percentage of
participants who reported engaging in risky
sex decreased and knowing their partner’s
HIV status increased for both HIV-positive
and HIV-negative participants.
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Table 1. Cont.
Study Design and Quality Included Studies Population Intervention Results/Outcomes
Should Voluntary Testing for HIV Infection be Offered to all Recently Arrived Migrants to the EU/EEA?
AHRQ 2012 [28] Systematic ReviewAMSTAR 9/11
n= 42
1. Amaro et al. (before-after, n = 939, United States of America).
2. Anglemyer et al. (systematic review, n = 8).
3. Bedimo et al. (observational, n = 19,424, United States of America).
4. Brogly et al. (before–after, n = not reported, Canada).
5. Camoni et la (before–after, n = 487, Italy).
6. Cohen et al. (RCT, n = 1763, Botswana, Kenya, Malawi, South Africa,
Zimbabwe, India, Brazil, Thailand, and United States of America).
7. Cunningham et al. (cross sectional, n = 300, United States of America).
8. Data collection on Adverse events of Anti-HIV Drugs (DAD) study group
(observational, n = 33,308, North America, Europe, and Australia).
9. Das et al. (cohort, n = 12,512, United States of America).
10. Del Romero et al. (cross sectional, n = 625, Spain).
11. Donnell (pre-post, n = 3381, Botswana, Kenya, Rwanda, South Africa,
Tanzania, Uganda, and Zambia).
12. Diamond et al. (cross sectional, n = 886, United States of America).
13. El-Bassel et al. (cRCT, n = 535, NR).
14. Elford et al. (cross sectional, n = 1687, United Kingdom).
15. Fideli et al. (case control, n = 109, Zambia).
16. Fisher et al. (cohort, n = 859, United Kingdom).
17. Fox et al. (before-after, n = 98, United Kingdom).
18. Goncalyes Melo et al. (cohort, n = 93, Brazil).
19. Haukoos et al. (cohort, n = not reported, United States of America).
20. Hernando et al. (cohort, n = 399, Spain).
21. HIV-CAUSAL (cohort, n = 62,760, 12 European cohorts).
22. Kihata et al. (cohort, n = 17,517, North America).
23. May et al.; Lanoy et al.; Moore et al. (cohort, n = 20,379,
Europe and North America).
24. Miguez-Burbbano et al. (cross sectional, n = 85, United States of America).
25. Montaner et al. (cohort, n = 5413, Canada).
26. Morin et al. (cross sectional, n = not reported, United States of America).
27. Musicco (cohort, n = 436, Italy).
28. Myers et al. (pre-post, n = not reported, United States of America).
29. Obel et al., Lohse et al., 2006 (observational, n = 2952, Denmark).
30. Reynolds et al. (cohort, n = 250, Uganda).
31. Ribaudo et al. (observational, n = 5056).
32. Severe et al. (RCT, n = 816, Haiti).
33. SMART (RCT, n = 477, USA/Europe).
34. Smit et al.; van Haastrecht et al. (cohort, n = 197, Amsterdam).
35. Sullivan et al. (cohort, n = 2993, Rwanda and Zambia).
36. Tun et al.; Vlahov et al. (before-after, n = 190, USA).
37. Wang et al. (cohort, n = 1927, China).
38. Weis et al. (corss sectional, n = not reported, United States of America).
39. When to Start Consortium (cohort, n = 45,691, Europe and North America).
40. White et al. (cohort, n-6479, United States of America).
41. Wood et al. (cohort, n = 2051, Canada).
42. Writing Committee for the CASCADE (Concerted Action on
SeroConversion to AIDS and Death in Europe) Collaboration
(cohort, n = 9455 Europe, Australia, and Canada).
Testing for asymptomatic
HIV infection in
Non-pregnant adults
and adolescents.
Screening Strategies
No randomized trial or observational study
compared clinical outcomes between adults
and adolescents screened and not screened for
HIV infection.
Some modeling studies have estimated the
cost-effectiveness of strategies involving
repeat screening.
No study directly evaluated the acceptability
of universal versus targeted HIV screening.
One study found universal, opt-out rapid
screening associated with higher likelihood of
testing compared with physician-directed,
targeted rapid screening (25% vs. 0.8%;
relative risk [RR], 30 [95% CI, 26 to 34]).
One study found universal testing associated
with a higher median CD4 count and lower
likelihood of CD4 count <0.200 × 109 cells/L
at the time of diagnosis compared with
targeted HIV screening, but these differences
were not statistically significant.
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Table 1. Cont.
Study Design and Quality Included Studies Population Intervention Results/Outcomes
Should Voluntary Testing for HIV Infection be Offered to all Recently Arrived Migrants to the EU/EEA?
Desai et al., 2015 [29] Systematic ReviewAMSTAR 6/11
n = 17
1. Bloomfeild et al. (observational, n = 399, United States of America).
2. Bourne et al. (observational, n = 3551, Australia).
3. Burton et al. (observational, n = 539, United Kingdom).
4. Cameron et al. (observational, n = 330, United Kingdom).
5. Cook et al. (RCT, n = 388, United States of America).
6. Downing et al. (RCT, n = 94, Australia).
7. Gotz et al. (RCT, n = 216, The Netherlands).
8. Gotz et al. (observational, n = 4191, The Netherlands).
9. Guy et al. (observational, n = 681, Australia).
10. Harte et al. (observational, n = 301, United Kingdom).
11. La Montagne (observational, n = 592, United Kingdom).
12. Malotte et al. (RCT, n = 499, United States of America).
13. Paneth-Pollak et al. (observational, n = 6220, United States of America).
14. Sparks et al. (RCT, n = 122, United States of America).
15. Walker et al. (observtional, n = 1116, Australia).
16. Xu et al. (RCT, n = 1215, United States of America).
17. Zou et al. (observational, n = 4179, Australia).
HIV-negative or unknown
status in all countries;
Hospitals, sexual health
clinics, general practice,
community venues, and
home sampling/testing
Active recall
SMS: OR for retesting as compared to the
control group ranged between 0.93 (95% CI
0.65 to 1.33) and 5.87 (95% CI 1.16 to 29.83).
The pooled OR among the observational
studies was 2.19 (95% CI 1.47 to 3.23).
A pooled OR for retesting among SMS group
is 5.66 (95% CI 1.78 to 17.99) among 126.
Phone calls: phone calls and verbal advice and
counseling had higher rates of retesting
OR = 2.50 (95% CI 1.3 to 4.8) compared to
phone calls only. Groups receiving phone calls
and verbal advice had higher rates if retesting
OR = 14.0 (95% CI 1.63 to 120.09) compared to
phone calls only.
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Table 2. Characteristics of included studies (cost-effectiveness). AIDS—acquired immunodeficiency syndrome.
Study Quality/Drummond Score Design Population Intervention Cost Effectiveness Resource Requirements
What are the Cost-Effectiveness and Resource Requirements of HIV Testing?
Farnham et al.,
1996 [30]
Allowance was made for uncertainty, sensitivity
analysis performed around a variety of
model inputs.
One-way sensitivity analysis in a decision
analytic framework.
Sensitivity analysis compares basic value with the
breakeven value that makes the two strategies
equally cost-effective. No range of values tested
and no a priori justification for values tested in
sensitivity analysis.
There was no assumed range, as noted above,
but results seem to be sensitive to plausible
changes in some model inputs, especially waiting
and counselling times.
Decision analytic
model, societal
perspective. Costs
measured in 1992
U.S. dollars.
United States
of America
ELISA test, and
counselling and
testing (C/T) vs.
rapid C/T vs.
no intervention
ELISA C/T: Average not
incremental cost-effectiveness
ratios: $1165 per correctly
identified case vs.
no intervention; rapid C/T
$940 per correctly identified case
Rapid vs. ELISA: $596 per
correctly identified case
ELISA C/T: positive individual
$103 per person, negative
individual $33.
Rapid C/T: positive individual
$135 per person, negative individual
$33 per person.
Low to moderate costs of
both strategies.
Kassler et al.,
1997 [31]
No allowance was made of uncertainty.
No sensitivity analyses.
Cost comparison,
societal perspective.
Comparison of testing
strategies in an HIV
clinic. Costs measured
in 1993 U.S. dollars.
Individuals attending
an anonymous testing
clinic and a sexually
transmitted disease
(STD) clinic in
Dallas, Texas
Standard C/T vs.
rapid C/T
No incremental
cost-effectiveness ratio
calculated, not a full
economic evaluation.
Cost per person receiving results
and counselling: standard $151,
rapid $131.
Low to moderate cost savings of
rapid C/T over standard C/T.
Wilkinson et al.,
1997 [32]
No allowance was made for uncertainty.
No sensitivity analyses.
Cost comparison,
prospective comparison
of testing strategies in
a South African
hospital. Costs
measured in 1996 South
African rand.
Resource-poor setting:
adult inpatients of
a rural South African
district hospital
ELISA C/T vs. single
rapid C/T vs. double
rapid C/T.
The double rapid
strategy consists of
two different rapid
tests: a Capillus test
and an Abbott test.
N/A
Cost per person counselled post-test:
single rapid R 14–31.2, double rapid
R 45.2, ELISA R 83.8.
Cost savings of single rapid test.
Kallenborn et al.,
2001 [33]
Some allowance made for uncertainty.
Sensitivity analysis limited and discursive.
Not statistically rigorous.
No range of values for sensitivity
analysis provided.
Results overall not sensitive to whether basic or
expanded regimen used, but as noted sensitivity
analysis was incomplete.
Cost comparison study,
retrospective chart
review of Health Care
Workers in
an emergency
department. Costs
measured in 1999
U.S. dollars.
Healthcare workers Rapid testing vs.ELISA testing
N/A. This is just a
cost comparison
Total costs for 17 patients: ELISA
$5966, Rapid test $466.
Cost savings of switching from
ELISA testing to rapid testing in
health care workers.
Ekwueme et al.,
2003 [34]
Allowance made for uncertainty.
One-way sensitivity analysis performed in a cost
analysis model.
Range of sensitivity analysis is +/− 50% of the
base value, or as wide as possible in the absence
of hard data.
Rank order of two-step rapid relative to standard
C/T sensitive to the return rate for standard C/T,
but one-step rapid consistently least expensive.
Cost analysis study
using a decision
analysis model, costs
estimated from both
societal and
provider perspective,
in 2000 U.S. dollars
United States
of America
Standard ELISA C/T
vs. both one-step
(multiple rapid
assays) and two-step
rapid C/T
(i.e., with a confirmatory
Western blot test)
N/A
From both a provider and societal
perspective, costs vary based on
sero-status. However, one-step rapid
testing is consistently the lowest cost
option, and two-step rapid testing
tends to be the highest cost.
There appear to be cost savings of
using a one-step rapid C/T protocol
vs. standard ELISA testing or
two-step rapid C/T.
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Table 2. Cont.
Study Quality/Drummond Score Design Population Intervention Cost Effectiveness Resource Requirements
What are the Cost-Effectiveness and Resource Requirements of HIV Testing?
Doyle et al., 2005 [35]
Allowance made for uncertainty.
One-way sensitivity analysis on “sensitivity,
specificity, and positive predictive values of each
screening test and confirmatory Western blot test,
the costs of each test, and the costs of treatments”
in a decision analytic model.
Range of values tested in sensitivity analysis
appears to be based on published estimates but
this is not explicitly stated.
The Oraquick rapid test is the dominant strategy
over a wide range of assumptions. Results not
sensitive to plausible changes.
Decision analysis
techniques:
decision tree
Low risk Mexican
American population,
incidence 0.05%
(1) testing with
enzyme linked
immunosorbent assay
that was confirmed
by Western blot
(2) testing with
Oraquick
rapid testing that was
confirmed by
Western blot
Oraquick as the primary
screening test for the unknown
HIV status of women who were
in labor was the most
cost-effective at $217,718 per HIV
case that was prevented.
Assuming a 70-year lifespan, this
equals $3111 per life-year gained.
Oraquick cost $98 spent for each
child who was HIV negative, ELISA
screening cost $491.
High cost of ELISA screening in
a low-prevalence Mexican American
population were from unnecessary
treatment of women and infants
with false-positive test results.
Oraquick has a relatively
modest costs.
Paltiel et al., 2005 [36]
Allowance made for uncertainty
One-way sensitivity analysis performed.
Range of estimates seems to be derived from
published estimates/a plausible a priori estimate.
Not explicitly stated.
Some sensitivity to assumptions regarding
background therapy, adherence to ARV therapy,
and rates of linkage to care. This does not
significantly change the results, may simply
change whether screening every three or five
years is preferable. Results regarding rapid vs.
conventional testing are unclear and sensitive to
plausible changes in background testing rates,
acceptance and linkage to care, and rate of
secondary transmission.
A stochastic model
(individual model) of
HIV screening and
treatment:
The cost-effectiveness
of preventing AIDS,
and a complications
model (CEPAC model)
United States
of America
(i) routine, voluntary
HIV, CTR
(counselling, testing
and referral);
(ii) current practice:
background testing
OR presentation with
opportunistic
infections in three
target populations:
Compared to current practice,
current practice plus one time
ELISA costs $36,000 per
Quality-Adjusted Life Year
(QALY) gained; current practice
plus ELISA every 5 years costs
$50,000 per QALY gained;
current practice plus ELISA
every 3 years costs $63,000;
current practics plus ELISA
every year costs $100,000 per
QALY gained
For HIV infected persons only:
current practice costs: $78,100
lifetime cost per person; current
practice plus one time ELISA costs
$80,700; current practice plus ELISA
every five years costs $89,000;
current practice plus ELISA every
3 years costs $92,500; current
practices plus ELISA every year
costs $98,600
For general population: current
practice costs $32,700 lifetime cost
per person, current practice plus
one-time ELISA costs $33,800;
current practice plus ELISA every
five years costs $37,300 current
practice plus ELISA every three
years costs $38,900; current practices
plus ELISA every year costs $41,700.
More frequent screening produced
large costs, due to screening test cost
plus the cost of managing
false positives.
Vickerman et al.,
2006 [37]
Allowance made for uncertainty.
Univariate sensitivity analysis for a number of
dimensions.
Model input ranges derived from
published estimates.
The cost-effectiveness of the POC rapid test is
sensitive to test cost.
Dynamic
compartmental model Female sex workers
A range of
sensitivities of point
of care (POC) tests.
If the POC test cost $2 per test
(2004 $US), and was 70%
sensitive, then POC test would
cost $152 per additional HIV
infection averted, which is
cost-effective.
If the cost of the POC test was $1
and the sensitivity was 80%, the
cost per HIV infection averted
would have been $58, which is
cost-effective.
When the POC test has a low
sensitivity, of 50%, POC is not
cost-effective.
Possible cost savings from using
POC tests include the reduction in
the number of STI clinic attenders
receiving treatment.
Assuming each test takes an extra
0.3 h to undertake, POC testing costs
for 4 years is $13,399 if the test cost
$1 and $34 621 if the test cost $3
(in 2004 U.S.$).
Moderate costs.
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The U.S. Agency for Healthcare Research and Quality (AHRQ) systematic review reported that
prior studies have shown that HIV testing was accurate (Rapid Test >90% sensitive, Western blot and
ELISA >99% sensitive) [28]. However, the review found that targeted screening programmes, which test
patients with identified risk factors, may still have missed a proportion of cases [28]. The universal
opt-out rapid testing strategy was associated with a higher likelihood of testing compared with
physician-directed, targeted rapid testing (25% vs. 0.8%; relative risk [RR] = 30 [95% CI: 26 to 34]),
but not necessarily in marginalised populations [28]. Universal testing was also associated with
a higher median CD4 count and lower likelihood of CD4 count <200 cells/mm3 at the time of diagnosis,
compared with targeted HIV testing, but these differences were not statistically significant [28].
New HIV diagnoses detected through universal testing in the United States had follow-up rates
that were reported to be between 75–100% [28]. One study directly compared universal and targeted
testing strategies [40]. Both the universal and targeted strategies resulted in very high rates of follow up
(defined as attending at least one HIV clinic visit) between 97% and 100% [40]. The sample sizes of the
included studies were small (range of 17–74 newly diagnosed HIV infections). The U.S. AHRQ review
also reports that the treatment was very effective at improving clinical outcomes in adolescent and
adult patients with advanced immunodeficiency [28]. The evidence indicates, from primary studies of
included systematic reviews, that treatment reduced the risk of AIDS-defining events and mortality
in persons with less advanced immunodeficiency and reduced sexual transmission in discordant
couples [41].
In the EU/EEA, migrants from HIV-endemic countries were at a high risk of HIV infection [42].
The groups identified as having a high HIV prevalence were people originating from Sub-Saharan
African, Latin America, Southeast Asia, and Eastern Europe [2,42]. These migrants had a higher
frequency of delayed HIV diagnosis and are more vulnerable to the negative effects of the disclosure of
their HIV status [42]. For migrants from countries where HIV prevalence is low, their socio-economic
vulnerability put them at risk of acquiring HIV post-migration [42]. Migrants tended to report high-risk
behaviour for HIV, such as multiple sexual partners, low and inconsistent condom use, high alcohol
consumption, and drug use [42]. Men who have sex with men (MSM); sex workers, both male and
female; and migrant women are considered particularly vulnerable populations within this group [42].
One systematic review and meta-analysis focused on the effectiveness of rapid tests for high-risk
populations for HIV exposure. One of the RCTs included migrants-specific [38], and the others
involved high-risk marginalised populations. The results of the included systematic review found that
rapid voluntary counselling and testing was associated with a large increase in HIV-testing uptake
and receipt of results in comparison to conventional testing (RR = 2.95, 95% CI: 1.69–5.16), but these
studies did not report on uptake of HIV treatment [26]. The GRADE quality of the included studies
was assessed to be low, because of the risk of bias and imprecision. All of the harms of rapid testing
were not considered for the scope of the present review.
Repeat testing was found to be more likely among the individuals where rapid testing was
performed (RR = 2.28, 95% CI 0.35 to 15.07) [26]. Retesting was also more likely for the individuals
who were reminded to re-test by short message service (SMS) text messaging (pooled Odds ratio (OR)
2.19 [95% CI 1.46 to 3.29]) [29]. Receiving phone calls, verbal advice, and/or counselling also resulted
in higher rates of retesting than phone calls alone (OR 2.50 [95% CI 1.3 to 4.8]) [29]. In the communities
where rapid HIV testing was implemented, the HIV incidence decreased by 11% in comparison to the
control arm communities [26]. The evidence for the uptake of HIV testing, receipt of results, and repeat
testing were considered of moderate quality, because of randomisation and allocation concerns. In the
review that addressed provider initiated treatment and counselling (PITC), nineteen studies were
included, all from Sub-Saharan Africa (n = 15) or Asia (n = 4) [27]. The majority (13/19) of studies were
conducted before the WHO PITC guidelines were developed in 2007, indicating that provider-initiated
testing was occurring in many locations prior to the publication of global guidance. All of the studies
that reported rates of HIV testing uptake showed increases in the HIV testing uptake associated with
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a PITC approach. The PITC’s impact on other outcomes does not appear to be worse than voluntary
counselling and testing (VCT).
Cost-Effectiveness
Three studies reported the cost-effectiveness of HIV testing strategies. Ekwueme [34] compared
the costs of three HIV counselling and testing technologies, standard, one-step, and two-step rapid
protocols. The standard protocol (i.e., ELISA) plus counselling and treatment, or one-step testing,
was found to be less expensive than the third technology for all of the plausible ranges of HIV
seroprevalence [34]. In low prevalence settings, a single rapid assay was cost-effective, as no follow-ups
were required nor the use of the expensive Western blot confirmatory assay [34]. The second study,
by Doyle [35], compared testing with an enzyme linked immunosorbent assay to rapid testing
with Oraquick. In a low prevalence Mexican setting of 0.05%, rapid testing with Oraquick was the
cost-effective strategy, at $217,718 per HIV case prevented. Assuming a 70-year lifespan, this equated
to $3111 per life-year gained [35]. The third study, by Paltiel [36], compared testing with ELISA to
the current practice (background testing OR presentation with opportunistic infections), in high (3%)
prevalence, medium (1%) prevalence, and low (0.1%) prevalence settings. The addition of a one-off
ELISA test was cost-effective compared to the current practice, for prevalence rates of 3% and 1%,
but not cost-effective at a prevalence rate of 0.05% (incremental cost-effectiveness ratio: $113,000/QALY
(Quality-adjusted Life Year) gained) [36].
The evidence supporting multiple rapid-tests, rather than a single rapid test followed by later
confirmatory test if positive, were mixed. One study supported the use of a single rapid test [32],
while another suggested possible cost savings with multiple rapid assays [34]. In this study, however,
the cost advantage of multiple rapid assays was sensitive to HIV seroprevalence. In low prevalence
settings (<0.1%), a single rapid assay was likely to be cost effective. The rapid tests evaluated in
early economic studies were generally reported to have a lower sensitivity than ELISA tests [30,33].
Rapid testing is expanding to self-administered oral swabs. Of the limited economic evidence regarding
rapid test false positives, one study [35] indicated a predictive value of 100% of the Oraquick rapid
test, even in a low prevalence population (as low as 1 in 1000). Another study [36] assigned a loss of
14 quality-adjusted days to patients who received a false positive result from rapid testing.
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Table 3. Recommendations Assessment, Development, and Evaluation (GRADE) evidence profile.
Certainty Assessment Effect
Certainty ImportanceNo. of
Studies
Study
Design Risk of Bias Inconsistency Indirectness Imprecision
Other
Considerations
Relative
(95% CI) Absolute (95% CI)
Outcome: Testing Uptake (follow up: 7 to 24 months)
3 (9745
participants)
Randomised
trials
Serious concerns, allocation
concealment was unclear, blinding of
intervention not possible,
and inability to determine blinding
of researchers
No serious
inconsistency
No serious
indirectness
No serious
imprecision
No other
concerns
RR 2.95
(1.69 to 5.16)
Without rapid
testing for HIV
With rapid
testing for HIV Difference
Moderate Critical
General population
0.1% 0.3% (0.2 to 0.5)
0.2% more
(0.1 more to
0.4 more)
High risk population
2.0% 5.9%(3.4 to 10.3)
3.9% more
(1.4 more to
8.3 more)
Outcome: HIV incidence (follow up: 36 months)
1 (8324
participants)
Randomised
trial
Serious concerns Allocation
concealment was unclear, blinding of
intervention not possible and inability
to determine blinding of researchers
No serious
inconsistency
No serious
indirectness
Serious
imprecision
No other
concerns
RR 0.89
(0.63 to 1.24)
Low risk population
Low Critical
7.2% 6.4% (4.5 to 8.9)
0.8% fewer
(2.7 fewer to
1.7 more)
The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI—confidence interval; RR—risk ratio; GRADE working group grades of evidence: high quality: we are very confident that the true effect lies close to that of the estimate of the effect;
moderate quality: we are moderately confident in the effect estimate, the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different;
low quality: our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect; very low quality: we have very little confidence
in the effect estimate, the true effect is likely to be substantially different from the estimate of effect. Interpreting relative values (e.g., uptake of testing) from the summary of findings
table: relative risk: (RR 2.98; 95% CI: 1.69–5.16)-three RCTs included in the analysis provided consistent point estimates showing that the uptake of testing was 2.95 times better among
participants randomized to rapid testing approaches.
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4. Discussion
Our systematic review provides insight into HIV testing strategies to improve access and uptake in
migrant populations in the EU/EEA, following the effectiveness and cost-effectiveness considerations.
In relation to our first research question, there were several HIV testing approaches. The literature
showed three leading strategies, rapid testing, conventional testing, and universal testing approaches.
Voluntary rapid tests improve HIV testing and uptake and have the potential to improve linkage to
counselling and treatment for migrant populations. The universal opt-out testing approach has good
intentions but lacks community outreach. Given the effectiveness of HIV treatment, measures and
strategies are needed in order to increase the uptake of testing and to reduce the late diagnosis among
migrant populations. However, heterogeneity between the results of the rapid testing approaches
(I2 of 93–99% in Figure 2) and limited EU/EEA-specific data suggest inconsistency between studies,
thereby limiting our confidence in the transferability of these results across the EU/EEA migrant
population contexts. The cost-effectiveness of the intervention, however, suggests that rapid testing
is preferable to conventional testing in several contexts, due, in particular, to effective testing and
counselling integration.
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There is no data on the cost-effectiveness and resource requirements of HIV testing in migrant
populations in the EU/EEA. Indirect evidence from the United States and South Africa provide some
insight into the resources required. We identified three studies on HIV testing strategies [34–36].
The economic evidence suggests that rapid testing is likely preferable to conventional testing across
a range of contexts, largely due to the ability to more effectively integrate testing and counselling.
One study supported the use of a single rapid test [32], while another suggested possible cost savings
with multiple rapid assays [34]. The evidence supporting multiple rapid-tests, rather than a single
rapid test followed by a later confirmatory test if positive, is mixed. In low prevalence settings (<0.1%),
a single rapid assay may still be cost effective.
4.1. Implementation Issues
Identifying and addressing potential barriers to implementing effective and cost-effective HIV
testing strategies can further promote access and uptake. Barriers to testing at organisational, provider
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(cultural competency), patient, and community levels in Europe include a perception of low risk,
fear and stigma of the disease and disclosure, discrimination, financial limitations, poor access to
care, lack of knowledge of where to obtain testing, and entitlement to medical care due to migration
status [3,43,44]. The uncertain migration status among migrants to Europe is a barrier to preventive
and health services in the EU/EEA [13,45]. This is especially true of undocumented migrants in the
EU/EEA, as their uncertain legal status results in precarious living conditions, and discovery of their
HIV status may risk deportation in certain countries [46]. HIV-related stigma is a significant barrier
to HIV testing, in addition to challenges with socio-economic status, language barriers, and a poor
understanding of European healthcare systems [44]. For many migrants, the barriers outweigh the
advantages of testing and treatment [47], further perpetuating the HIV testing problem.
Migrant [13] populations in Sub-Saharan African [48] were more likely to be tested for HIV
if they were of poor health, lost a child or sexual partner to HIV, ART was available, testing was
a requirement for marriage preparation, enhanced confidentiality, had strong social networks and
support [13,48], and had a history of sexually transmitted infections (STIs) [44]. Increasing cultural
sensitivity and community engagement in counselling and in community-based approaches with
outreach and mobilisation, were highlighted as ways to address and promote access and uptake [15],
reflecting the WHO recommendations for vulnerable populations. More equity oriented research is
needed to identify barriers to HIV testing in EU/EEA.
The ECDC antenatal screening for HIV, hepatitis B, syphilis, and rubella susceptibility highlights
routine HIV testing for all pregnant women [49]. Certain high income countries such as the United
States, Australia, Ireland, and Canada recommend testing refugees from HIV endemic areas within one
month of arrival in primary health care settings. Such countries have national recommendations [50–53]
for counselling and testing for refugee and migrant populations. Providing HIV testing during routine
consultations was generally appreciated by users as an acceptable way to address user inhibitions in
asking for it. Several Latin American migrants in Europe deemed compulsory testing as an acceptable
public health measure, while healthcare practitioners reported feeling unprepared to communicate
HIV positive results and adjust the flow of care [54]. Most migrants who reported knowing how to
access HIV testing, preferred to receive information directly from community practitioners [55].
In general, HIV testing is cost-effective compared with no testing; the current focus is on which
testing strategies are the most cost-effective in a migrant health context. The cost-effectiveness of
rapid vs. conventional counselling and testing strengthens the need to increase access and uptake.
The sensitivity analyses and analytic frameworks, however, were limited and demonstrate how this
field is dynamic, as new rapid oral tests emerge. The cost-effectiveness data of rapid HIV testing in
the EU/EEA were not available, but economic evidence about the integration of counselling, testing,
and treatment was promising. The precise costs and benefits associated with rapid testing in a variety
of EU/EEA member state contexts should be evaluated more closely in high-quality economic studies
that directly compare various rapid testing assays to conventional testing with ELISA. Such research
would need to provide quantitative evidence of the incremental cost-effectiveness of various strategies,
including the uncertainty around these estimates.
4.2. Public Health Considerations
It is of particular importance to consider the challenges faced by undocumented migrants in
order to increase the access and uptake of HIV testing and treatment programmes in the EU/EEA.
We know from large clinical trials that treatment reduces onward transmission by 96% [56]. People
living with undiagnosed HIV infection and those diagnosed with HIV but not yet on treatment
contribute disproportionately to the number of new HIV infections [57]. Some of the contributing
structural/organisational barriers to testing include a lack of migration status, lack of funding,
availability of community based services, and discrimination in entitlement to care. More than half
of the EU/EEA countries do not provide ART for undocumented migrants [12], further exacerbating
the issue and reducing the likelihood that these individuals will come forward for testing. Certain
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EU/EEA countries have initiated public health screening programmes for migrants at high risk for
HIV infection. The benefits of HIV testing in migrants, at both individual and community levels
are recognized by many EU/EEA countries, but developing suitable and comprehensive migrant
screening programmes has been a challenge in many countries [13].
4.3. Strengths and Limitations
One of the strengths of this review is that it has used GRADE methodology to assess the certainty
of the evidence of the included studies, including recent systematic reviews from the U.S. AHRQ and
the WHO guidelines, in combination with recent reviews on rapid testing. This review’s strengths lie
in identifying barriers to accessing testing, and highlighting the cost-effectiveness of increasing the
uptake of HIV testing for migrants. The barriers reported from Europe align with migrant HIV access
barriers in other high-income countries.
We identified no migrant-specific HIV screening studies and therefore focused on studies that
considered high HIV prevalence populations, many of which considered non EU/EEA migrants.
This may limit the transferability of the findings to the EU/EEA context. We also acknowledge the lack
of economic evidence for HIV testing approaches in migrants to the EU/EEA. The economic evidence
is most relevant to the health system in which the study was undertaken, and therefore non-European
studies may not be transferable. In addition, a few studies were more than twenty years old, and the
costs may have changed since the resource use data was collected.
5. Conclusions
The migrants coming from countries with a high HIV prevalence often arrive with HIV related
stigma and fear, and the screening and testing approaches need to address this challenge. HIV testing
approaches that incorporate voluntary rapid testing programmes and primary care testing for high risk
migrant populations may increase the uptake of testing, support timely diagnoses, and should provide
more opportunities for linkage to effective treatment among migrant populations. All of the testing
strategies may improve early diagnosis; treatment improves the individual’s clinical outcomes, reduces
AIDS-defining events’ morbidity, and decreases mortality rates from HIV-related events, as well as
having a clear public health benefit. Voluntary testing with rapid results offers an opportunity to
overcome HIV related stigma in communities with high HIV prevalence compared to the conventional
techniques for HIV testing alone.
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Appendix B Search Strategy
Database: Ovid MEDLINE(R) 1946 to Present with Daily Update
Search Date: 8 April 2016
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2. (huma adj (immunedeficienc$ or immune deficienc$ or immunodeficienc$ or immuno
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4. (acquired adj (immunedeficienc$ or immune deficienc$ or immunodeficienc$ or immuno
deficienc$)).tw. (20,316)
5. aids.hw. (59,809)
6. (aids adj2 (infect$ or virus$)).tw. (5953)
7. or/1–6 (346,871)
8. exp Mass Screening/(107,701)
9. (screened or screening?).tw. (417,187)
10. Early Diagnosis/(18,989)
11. [or/8–15] (0)
12. [or/17–19] (0)
13. [remove duplicates from 24] (0)
14. (hiv or hiv1$ or hiv2$).mp. (277,362)
5. (human adj (immunedeficienc$ or immune deficienc$ or immunodeficienc$ or immuno
deficienc$)).tw. (72,052)
16. Acquired Immunodeficiency Syndrome/(74,163)
7. (acquired adj (immunedeficienc$ or immune deficienc$ or immunodeficienc$ or immuno
deficienc$)).tw. (20,316)
18. aids.hw. (59,809)
19. (aids adj2 (infect$ or virus$)).tw. (5953)
20. or/14–19 (346,871)
21. exp Mass Screening/(107,701)
22. (screened or screening?).tw. (417,187)
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23. Early Diagnosis/(18,989)
24. ((case? or early) adj2 (detected or detection? or diagnos$ or discover$)).tw. (149,145)
25. exp Population Surveillance/(55,996)
26. (disease? adj2 surveillance).tw. (4047)
27. Contact Tracing/(3517)
28. contact tracing.tw. (1151)
29. or/21–28 (646,541)
30. meta analysis.mp,pt. (90,987)
31. review.pt. (2,033,544)
32. search$.tw. (253,118)
33. or/30–32 (2,219,856)
34. animals/not (humans/and animals/) (4,191,261)
35. 33 not 34 (2,063,224)
36. 20 and 29 and 35 (3419)
37. 36 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).ed. (1178)
38. remove duplicates from 37 (1137)
***************************
Database: Embase <1980 to 7 April 2016 >
Search Date: 8 April 2016
1. (hiv or hiv1$ or hiv2$).mp. (313,646)
2. exp Human immunodeficiency virus infection/(322,600)
3. exp Human immunodeficiency virus/(156,358)
4. (human adj (immunedeficienc$ or immune deficienc$ or immunodeficienc$ or immuno
deficienc$)).tw. (81,168)
5. (acquired adj (immunedeficienc$ or immune deficienc$ or immunodeficienc$ or immuno
deficienc$)).tw. (22,202)
6. aids.hw. (11,098)
7. (aids adj2 (infect$ or virus$)).tw. (6778)
8. or/1–7 (447,157)
9. exp mass screening/(178,092)
10. (screened or screening?).tw. (612,553)
11. anonymous testing/(221)
12. early diagnosis/(82,014)
13. ((case? or early) adj2 (detected or detection? or diagnos$ or discover$)).tw. (223,587)
14. exp health survey/(182,039)
15. (disease? adj2 surveillance).tw. (5133)
16. contact examination/(2820)
17. contact tracing.tw. (1443)
18. or/9–17 (1,076,977)
19. meta analys$.mp. (166,352)
20. search$.tw. (360,207)
21. review.pt. (2,126,810)
22. or/19–21 (2,466,318)
23. animals/not (humans/and animals/) (1,150,973)
24. 22 not 23 (2,401,775)
25. 8 and 18 and 24 (5168)
26. 25 and (2010$ or 2011$ or 2012$ or 2013$ or 2014$ or 2015$ or 2016$).dd. (2136)
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27. remove duplicates from 26 (2080)
***************************
Databases: Database of Abstracts of Reviews of Effects (DARE) and Cochrane Database of Systematic
Reviews (CDSR)
Search Date: 20 March 2016
ID Search
#1 (hiv or hiv1* or hiv2*) (15,056)
#2 human next (immunedeficienc* or immune deficienc* or immunodeficienc* or immuno
deficienc*):ti,ab (2799)
#3 MeSH descriptor: [Acquired Immunodeficiency Syndrome] this term only (1248)
#4 acquired next (immunedeficienc* or immune deficienc* or immunodeficienc* or immuno
deficienc*):ti,ab (646)
#5 aids:kw (2253)
#6 aids near/2 (infect* or virus*):ti,ab (457)
#7 #1 or #2 or #3 or #4 or #5 or #6 (16,330)
#8 MeSH descriptor: [Mass Screening] explode all trees (5443)
#9 (screened or screening*):ti,ab (22,416)
#10 MeSH descriptor: [Early Diagnosis] this term only (538)
#11 (case* or early) near/2 (detected or detection* or diagnos* or discover*):ti,ab (3639)
#12 MeSH descriptor: [Population Surveillance] explode all trees (709)
#13 disease* near/2 surveillance:ti,ab (30)
#14 MeSH descriptor: [Contact Tracing] this term only (96)
#15 contact tracing:ti,ab (30)
#16 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 (27,248)
#17 #7 and #16 (1173)
#18 #17 in Other Reviews (27)
#19 #17 in Cochrane Reviews (Reviews and Protocols) (195)
***************************
Database: EBSCO CINAHL <1970 to April 2016>
Search Date: 8 April 2016
S27 S23 AND S26 297
S26 S24 OR S25 2,588,490
S25 EM 2010 or EM 2011 or EM 2012 or EM 2013 or EM 2014 or EM 2015 or EM 2016 2,411,599
S24 PY 2010 or PY 2011 or PY 2012 or PY 2013 or PY 2014 or PY 2015 or PY 2016 2,338,383
S23 S8 AND S16 AND S22 527
S22 S17 OR S18 OR S19 OR S20 OR S21 220,800
S21 (TI meta analy* or AB meta analy*) 29,599
S20 (MH “Meta Analysis”) 24,899
S19 PT review 141,121
S18 PT systematic review 53,358
S17 (MH “Systematic Review”) 37,370
S16 S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 154,560
S15 contact tracing 1457
S14 (disease* or population) N2 surveillance 18,647
S13 (MH “Population Surveillance+”) 5939
S12 (case* or early) N2 (detected or detection* or diagnos* or discover*) 29,738
S11 (MH “Early Diagnosis”) 4469
S10 TI ((screened or screening*)) OR AB ((screened or screening*)) 78,064
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S9 (MH “Health Screening+”) 62,689
S8 S1 OR S2 OR S3 OR S4 OR S5 S6 OR S7 108,656
S7 TX aids N2 (infect* or virus*) 10,961
S6 MW aids 22,515
S5 TX acquired N1 (immunedeficienc* or immune deficienc* or immunodeficienc* or immuno
deficienc*) 21,283
S4 (MH “Acquired Immunodeficiency Syndrome”) 13,583
S3 TX human N1 (immunedeficienc* or immune deficienc* or immunodeficienc* or immuno
deficienc*) 23,570
S2 (hiv or hiv1* or hiv2*) 79,932
S1 (MH “Human Immunodeficiency Virus+”) 6511
Appendix C
Table A1. Population, intervention, comparison, and outcome (PICO) inclusion criteria.
Population: Migrants and refugees to EU/EEA countries (primary population of interest); willconsider indirect evidence of marginalized groups in settings of high HIV prevalence
Intervention: Voluntary testing for HIV
Outcome: Testing outcomes: testing uptake, HIV incidenceTreatment outcomes: Efficacy, withdrawals
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